

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)

13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Cancelled)
17. (Cancelled)
18. (Cancelled)
19. (Currently Amended) A drug eluting medical device comprising:
 - an implantable intraluminal structure;
 - a first polymeric solution;
 - a drug ~~pharmaceutically active agent~~, in therapeutic dosages, incorporated into the first polymeric solution creating a resulting mixture;
 - a separate and distinct antioxidant incorporated into the resulting mixture to substantially hinder degradation of the ~~pharmaceutically active agent~~ drug through oxidation, thereby creating a base coat with the antioxidant ~~physically~~ proximate the drug in the base coat ~~pharmaceutically active agent~~, the base coat being affixed to at least a portion of the implantable intraluminal structure; and
 - a second polymeric solution forming a top coat affixed to the base coat.
20. (Original) The drug eluting medical device according to claim 19, wherein the implantable intraluminal structure comprises a stent.
21. (Original) The drug eluting medical device according to claim 19, wherein the pharmaceutically active agent comprises a rapamycin.

22. (Withdrawn) The drug eluting medical device according to claim 19, wherein the pharmaceutically active agent comprises sirolimus.

23. (Cancelled)

24. (Previously Presented) The drug eluting medical device according to claim 19, wherein the antioxidant comprises Butylated Hydroxytoluene.

25. (Withdrawn) The drug eluting medical device according to claim 23, wherein the antioxidant comprises Tocopherols.

26. (Withdrawn) The drug eluting medical device according to claim 23, wherein the antioxidant comprises Ascorbic Acid.

27. (Withdrawn) The drug eluting medical device according to claim 23, wherein the antioxidant comprises Ascorbyl Palmitate.

28. (Withdrawn) The drug eluting device according to claim 19, wherein the stabilizing agent has an affinity for the pharmaceutically active agent.

29. (Withdrawn) The drug eluting device according to claim 19, wherein the stabilizing agent is mixed with the resulting solution such that the stabilizing agent is proximate the pharmaceutically active agent.

30. (Withdrawn) A drug eluting medical device comprising:
a stent;
a biocompatible polymeric solution;
rapamycin, in therapeutic dosages, incorporated into the polymeric solution, the resulting mixture being affixed to at least a portion of the stent;
and
an antioxidant incorporated into the resulting mixture to prevent degradation of the rapamycin.

31. (Withdrawn) The drug eluting medical device according to claim 30, wherein the antioxidant comprises Butylated Hydroxytoluene in the range from about 0.006 to about 0.02 percent weight by volume.

32. (Withdrawn) The drug eluting medical device according to claim 30, wherein the antioxidant comprises Tocopherol in the range from about 0.048 to about 0.102 percent weight by volume.

33. (Withdrawn) The drug eluting medical device according to claim 30, wherein the antioxidant comprises Ascorbyl Palmitate in the range from about 0.022 to about 0.508 percent weight by volume.

34. (Withdrawn) The drug eluting medical device according to claim 30, wherein the antioxidant comprises Ascorbyl Palmitate in the range from about 0.01 to about 0.02 percent weight by volume.

35. (Withdrawn) The drug eluting medical device according to claim 30, wherein the antioxidant comprises 250 ppm Butylated Hydroxytoluene.